Score Overview
Explore the 2021 public Archive ranking →
Where Regeneron Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Reached the top 50 on HDB Score in 2 years, the longest run being 1 in a row — but not in 2021.
- REGN
1996: 54.3% · 2021: 5.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 752.25 | — |
1 Year2025-09-26 | $ 561.02 | 34.09% |
5 Years2021-09-28 | $ 599.34 | 25.51% |
10 Years2016-09-28 | $ 415.18 | 81.19% |
20 Years2006-09-28 | $ 15.91 | 47x |
30 Years1996-09-27 | $ 19.19 | 39x |
All Time1991-04-02 | $ 20.93 | 35x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1991-04-02 |
|---|---|---|---|---|---|---|---|
| Price | $ 752.25 | $ 561.02 | $ 599.34 | $ 415.18 | $ 15.91 | $ 19.19 | $ 20.93 |
| Return | — | 34.09% | 25.51% | 81.19% | 47x | 39x | 35x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 15.53B | $ 4.32B | |
| 2025 | $ 14.34B | $ 4.50B | $ 8.60B |
| 2024 | $ 14.20B | $ 4.41B | $ 9.01B |
| 2023 | $ 13.11B | $ 3.95B | $ 10.84B |
| 2022 | $ 12.17B | $ 4.33B | $ 7.74B |
| 2021 | $ 16.07B | $ 8.07B | $ 5.69B |
| 2020 | $ 8.49B | $ 3.51B | $ 6.72B |
| 2019 | $ 7.86B | $ 2.11B | $ 3.21B |
| 2018 | $ 6.71B | $ 2.44B | $ 4.56B |
| 2017 | $ 5.87B | $ 1.19B | $ 2.89B |
| 2016 | $ 4.86B | $ 895M | $ 1.03B |
| 2015 | $ 4.10B | $ 636M | $ 1.67B |
| 2014 | $ 2.81B | $ 348M | $ 1.36B |
| 2013 | $ 2.10B | $ 424M | $ 693M |
| 2012 | $ 1.37B | $ 750M | $ 308M |
| 2011 | $ 445M | -$ 221M | $ 526M |
| 2010 | $ 459M | -$ 104M | $ 249M |
| 2009 | $ 379M | -$ 67M | $ 341M |
| 2008 | $ 238M | -$ 82M | $ 474M |
| 2007 | $ 125M | -$ 105M | $ 766M |
| 2006 | $ 63M | -$ 102M | $ 459M |
| 2005 | $ 66M | -$ 95M | $ 298M |
| 2004 | $ 174M | $ 41M | $ 295M |
| 2003 | $ 57M | -$ 107M | $ 293M |
| 2002 | $ 21M | -$ 124M | $ 264M |
| 2001 | $ 21M | -$ 76M | $ 385M |
| 2000 | $ 59M | -$ 23M | $ 117M |
| 1999 | $ 34M | -$ 23M | $ 66M |
| 1998 | $ 38M | -$ 8M | $ 19M |
| 1997 | $ 33M | -$ 11M | $ 28M |
| 1996 | $ 24M | -$ 32M | $ 34M |
| 1995 | $ 27M | -$ 23M | $ 32M |
| 1994 | $ 23M | -$ 30M | $ 23M |
| 1993 | $ 10M | -$ 39M | $ 12M |
| 1992 | $ 11M | -$ 19M | $ 16M |
| IPO1991 | $ 7M | -$ 4M | $ 26M |
Regeneron Pharmaceuticals Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 66M to $ 14.34B and net income went from -$ 95M to $ 4.50B. Revenue increased in 18 of those 20 years; net income in 11.
Between 1995 and 2025, revenue grew from $ 27M to $ 14.34B and net income went from -$ 23M to $ 4.50B. Revenue increased in 24 of those 30 years; net income in 15.
Regeneron Pharmaceuticals Inc currently holds a 20-year HDB Score of 7.8 out of 10. How the HDB Score is calculated.
Membership
Continue REGN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
